The miR-320a/PRDX3 Axis Alleviates the Oxidative Stress and Fibrotic Alterations in Fibroblasts in Thyroid Eye Disease
Investigative Ophthalmology & Visual Science · 14.07.2025 · 66 (9) · 41
DOI: 10.1167/iovs.66.9.41 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, erschienen am 14.07.2025. Verfasst von Shenghua Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Third Xiangya Hospital, Central South University, Yuelu District, Changsha, Hunan, People's Republic of China. Hauptthemen laut MEDLINE: MicroRNAs, Oxidative Stress, Graves Ophthalmopathy, Fibroblasts. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, The Third Xiangya Hospital, Central South University, Yuelu District, Changsha, Hunan, People's Republic of China.
Zitieren
APA
Liu, S., Yi, J., Lu, S., Cao, J., Xie, B., Tan, Y., & Xiong, W. (2025). The miR-320a/PRDX3 Axis Alleviates the Oxidative Stress and Fibrotic Alterations in Fibroblasts in Thyroid Eye Disease. Investigative Ophthalmology & Visual Science, 66(9), 41. https://doi.org/10.1167/iovs.66.9.41
Vancouver
Liu S, Yi J, Lu S, Cao J, Xie B, Tan Y, et al. The miR-320a/PRDX3 Axis Alleviates the Oxidative Stress and Fibrotic Alterations in Fibroblasts in Thyroid Eye Disease. Investigative Ophthalmology & Visual Science. 2025;66(9):41. doi:10.1167/iovs.66.9.41
BibTeX
@article{Liu2025,
author = {Liu, Shenghua and Yi, Jinping and Lu, Shiyao and Cao, Jiamin and Xie, Bingyu and Tan, Yao and Xiong, Wei},
title = {The miR-320a/PRDX3 Axis Alleviates the Oxidative Stress and Fibrotic Alterations in Fibroblasts in Thyroid Eye Disease},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
volume = {66},
number = {9},
pages = {41},
doi = {10.1167/iovs.66.9.41}
}
EUVIMED